Skip to main content

Table 1 Arithmetic mean of live tick counts and percent efficacy relative to placebo for dogs treated once orally with Simparica Trio™ at 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt)

From: Evaluation of the speed of kill of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced infestations of Ixodes scapularis on dogs

Count timea

Treatment group

Dayb

0

7

14

21

28

35

8 hours

Placebo

18.1

20.7d

21.6

19.1

17.7

17.7

Simparica Trio™

5.9

8.0d

17.1

13.9

17.1

16.8

% Efficacy

67.5

61.5d

20.6

27.3

3.1

5.0

Test statistic

t(9.71) = 2.19

t(6.99) = 5.18

t(40) = 0.84

t(12.3) = 1.29

t(13.7) = 0.23

t(7.68) = 0.75

P-valuec

0.0545

0.0013

0.4069

0.2191

0.8186

0.4751

12 hours

Placebo

21.3

23.6

18.9

21.2d

24.9

19.6

Simparica Trio™

0.3

3.6

7.7

8.0d

11.9

10.9

% Efficacy

98.4

84.9

59.4

62.2d

52.2

44.3

Test statistic

t(13.2) = 18.10

t(9.39) = 6.21

t(40) = 4.00

t(6.6) = 4.32

t(13.8) = 1.79

t(13.3) = 2.27

P-valuec

< 0.0001

0.0001

0.0003

0.0040

0.0957

0.0404

24 hours

Placebo

17.4

17.2

24.1

16.8

23.1

14.8

Simparica Trio™

0.1

0.1

0.0

0.3

1.3

4.8

% Efficacy

99.4

99.4

100

98.0

94.2

67.7

Test statistic

t(9.29) = 9.34

t(9.04) = 11.33

t(40) = 12.89

t(9.29) = 7.98

t(8.03) = 9.62

t(9.12) = 4.22

P-valuec

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

0.0022

  1. aTime after treatment or subsequent weekly tick infestations
  2. bDay of treatment (Day 0) and of subsequent weekly tick infestations
  3. cP-value for comparison of arithmetic mean tick counts between Simparica Trio™ and placebo groups at each time point within a row, P ≤ 0.05 indicates significant difference
  4. dTime point with missing observations, back-transformed least squares means and corresponding percent efficacy estimates were used